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Abstract
Botulinum neurotoxins (BoNTs), composed of a family of seven serotypes (categorized A – G),
are the deadliest of known biological toxins. The activity of the metalloprotease, light chain (LC)
component of the toxins is responsible for causing the life-threatening paralysis associated with
the disease botulism. Herein we report significantly more potent analogs of novel, lead BoNT
serotype A LC inhibitor 2,5-bis(4-amidinophenyl)thiophene (Ki = 10.88 μM ± 0.90 μM).
Specifically, synthetic modifications involved simultaneously replacing the lead inhibitor’s
terminal bis-amidines with secondary amines and the systematic tethering of 4-amino-7-
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chloroquinoline substituents to provide derivatives with Ki values ranging from 0.302 μM (± 0.03
μM) – 0.889 μM (± 0.11 μM).
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1. Introduction
Botulinum neurotoxins (BoNTs), a family of seven serotypes (categorized A – G), are
secreted by Clostridia species botulinum, baratii, and butyricum [1, 2], and are listed among
the highest priority of bioterrorism agents [3].
The enzymes are composed of a 100 kDa heavy chain (HC) and a 50 kDa light chain (LC),
which are tethered by a reducible disulfide bridge [4, 5]. The HC binds to neuronal receptors
and releases the LC into the cell cytosol [5–7]. The LC, a zinc2+ (Zn2+) metalloprotease,
cleaves neuron soluble N-ethylmaleimide-sensitive fusion protein attachment protein
receptor (SNARE) proteins [6, 7]. This proteolytic activity inhibits the release of
acetylcholine into neuromuscular junctions, resulting in the disease state botulism [6, 7]. The
BoNT serotype A LC (BoNT/A LC), which is the target enzyme of this study, cleaves
SNARE protein synaptosomal associated protein of 25 kDa (SNAP-25) [6, 7], and is known
to cause human botulism [8, 9].
We have previously reported the discovery of a variety of non-Zn2+ chelating BoNT/A LC
lead inhibitor chemotypes [10–15], many of which possess terminal di-cationic moieties
[11–14]. With respect to di-cationic inhibitors, the synthesis of more potent derivatives of
leads possessing bis-amidine and bis-imidazoline functional groups has been described [16–
19]. Importantly, the synthetic modification of one of these leads, bis[3-amide-5-
(imiazolino)phenyl]terephthalamide-based inhibitor I (Ki = 8.52 ± 0.53 μM) [18] (Figure 1),
via the incorporation of terminal -(CH2)3-4,7-ACQ components, resulted in derivative II
(Figure 1), which possesses a Ki = 0.572 μM ± 0.041 μM [18]. To the best of our
knowledge, II is the most potent, non-hydroxamic acid-based BoNT/A LC inhibitor reported
to date.
As part of an ongoing research program to discover novel BoNT/A LC inhibitor chemotypes
for development, a variety of di-amidine substituted compounds obtained from the National
Cancer Institute’s Open Repository were screened. Subsequently, 2,5-bis(4-
amidinophenyl)thiophene 1 (NSC 300510) (Scheme 1) was found to provide 78% BoNT/A
LC inhibition when tested at 20 μM concentration. Following, 1 was synthesized to ensure
purity, and subsequent in vitro testing indicated that it possesses a Ki = 10.88 μM ± 0.90
μM (Table 1).
Interestingly, 1 has previously been shown to possess anti-trypanosomal activity [20, 21],
and provided 100 % survival when administered as a single, 320 mg/kg dose during
Trypanosoma rhodesiense infection [21]. Additionally, 1 has been analyzed for
antineoplastic activity, and based on a dosing regimen of three 100 mg/kg injections
(administered on day one, and then every fourth day) was non-toxic to mice [22].
Therefore, based on the possibility of repurposing a biologically relevant chemotype, 1 was
chosen as a candidate for synthetic modification to provide derivatives with increased
BoNT/A LC inhibitory potencies. Specifically, based on the strategy used to increase the
inhibitory potency of lead I (Figure 1) [18], it was hypothesized that systematically tethering
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terminal 4,7-ACQ motifs to 1 with short methylene chains would also provide significantly
more potent derivatives.
2. Chemistry
Initially, we attempted to substitute -(CH2)n-4,7-ACQ components directly onto the terminal
amidines of 1. However, as previously encountered when attempting the same amidine
substitution with a different BoNT/A LC inhibitor chemotype [18], prohibitive synthesis
and/or degradation during purification were encountered. To circumvent these obstacles, an
alternative cationic motif, with the terminal amidines of 1 replaced with secondary amines,
provided an efficient synthetic route for the generation of a congeneric series to further test
our hypothesis for increasing the inhibitory potency of chemotype 1.
The synthesis of 1 and derivatives 4a – d are outlined in Scheme 1. Key intermediate di-
nitrile 2 was obtained in 94% yield by coupling 4-cyanophenylboronic acid and 2,5-
dibromothiophene under Suzuki conditions. The synthesis of 1, to ensure purity (as it was
initially obtained from a chemical repository (vide supra)), was achieved in two-steps by
reacting 2 with LHMDS at room temperature, followed by isolation as an HCl salt (97%
yield). Di-aldehyde 3 was prepared in 77% yield via the DIBAH-mediated reduction of 2 at
0°C. Following, simultaneous reductive amination of 3 and coupling with NH2-(CH2)n-4,7-
ACQ motifs provided targets 4a – d, which were isolated as TFA salts (yields ranged from
24 – 49 %).
3. BoNT/A LC inhibition
Table 1 provides the Ki values for inhibitors 1 and 4a – d when examined in vitro employing
a well documented HPLC-based assay for BoNT/A LC inhibition [23–29]. The potencies of
the derivatives, in support of our hypothesis, provide further evidence that tethering -
(CH2)n-4,7-ACQ components onto the termini of di-cationic lead BoNT/A LC inhibitors
(i.e., such as I (Figure 1)) and 1 (Scheme 1 and Table 1) can significantly improve inhibitory
potency. Interestingly, as was encountered when tethering 4,7-ACQ components onto the
terminal amides of inhibitor chemotype I [18] (Figure 1), trimethylene linkers also afforded
the most significant increase in the inhibitory potency of 1. Specifically, tethering -
(CH2)3-4,7-ACQ groups onto the secondary amino termini of the 2,5-bis(4-
methylaminophenyl)thiophene scaffold (4b, Scheme 1) increased inhibitory potency by
approximately (approx.) 36-fold versus 1 (Table 1).
Moreover, as was also previously observed for derivatives of I (Figure 1) [18], decreasing or
increasing the methylene tether length above or below that of trimethylenes also resulted in
decreased inhibitor 1 derivative potencies. For example, when the tethers were shortened to
dimethylenes (4a, Scheme 1), inhibitory potency decreased by approx. 3-fold versus 4b
(Table 1). Likewise, when tether lengths were increased to tetramethylenes (4c, Scheme 1),
inhibitory potency also decreased, but less dramatically than observed for 4a (Scheme 1)
(i.e., an approx. 1.8-fold decrease in potency versus 4b) (Table 1). Finally, derivative 4d
(Scheme 1), which possesses pentamethylene tethers, was approx. 3-fold less potent than 4b
(Table 1), and with respect to inhibitory potency, is equivalent to 4a (Table 1). Nevertheless,
it is noteworthy that regardless of the tether length, 4a – d are all significantly more potent
than lead 1 (Table 1).
The data from this study, and the previous study for developing more potent derivatives of
inhibitor I (Figure 1) [18], provide further evidence that using trimethylene tethers to link
4,7-ACQ moieties onto the termini of di-cationic BoNT/A LC inhibitors consistently results
in derivatives with significantly improved potencies versus dimethylene, tetramethylene, or
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pentamethylene tethers (Table 1). However, unlike the substitution pattern used to generate
more potent derivatives of I (Figure 1), the results from this research indicate that -
(CH2)n-4,7-ACQ components may be tethered directly onto the inhibitor’s two cationic
substituents to achieve increased potency. For example, II (Figure 1) is approx. 15-fold
more potent than I (Figure 1), while 4b is approx. 36-fold more potent than 1 (Table 1) –
even though the Ki values of the two leads (i.e., I (Figure 1) and 1 (Table 1)) indicate that
their inhibitory potencies are approx. equivalent. Additionally, the Ki values for 4a – d
indicate that lower pKa cationic amines may be used to translate μM range, di-amidine
substituted leads (such as 1 (Scheme 1)) into nM-range derivatives via an efficient synthetic
route (Scheme 1).
4. Conclusions
In summary, we report that tethering -(CH2)n-4,7-ACQ motifs onto the modified cationic
components of lead BoNT/A LC inhibitor 2,5-bis(4-amidinophenyl)thiophene (i.e., 1)
significantly increases derivative potencies. The data from this study corroborates and
further validates a previous report in which a similar strategy was used to translate a bis[3-
amide-5-(imidazolino)phenyl]terephthalamide-based BoNT/A LC lead inhibitor into
submicromolar-range derivatives [18]. However, in this study, we show that tethering -
(CH2)n-4,7-ACQ components directly onto the lead inhibitor chemotype’s terminal di-
cationic components provides a more pronounced increase in potency. The implications of
this research: such modifications may be made to a variety of our lead, di-cationic BoNT/A
LC inhibitors [10–15, 18, 30] to significantly increase derivative potencies. Finally, results
from this study preface future syntheses to optimize the elemental composition and rigidity
of the tethered components, i.e., beyond that of -(CH2)n-4,7-ACQ motifs.
5. Experimental section
5.1. Chemistry
Melting points were determined using a Boetius PMHK apparatus (Carl Zeiss, Germany)
and were not corrected. IR spectra were recorded on a Perkin-Elmer spectrophotometer
FTIR 1725X. 1H and 13C NMR spectra were recorded on a Varian Gemini-200 spectrometer
(at 200 and 50 MHz, respectively) and a Bruker Ultrashield Advance III spectrometer (at
500 and 125 MHz, respectively) employing indicated solvents (vide infra) using TMS as the
internal standard. Chemical shifts are expressed in ppm (δ) values and coupling constants (J)
in Hz. ESI–MS (HRMS) spectra of the synthesized compounds were acquired on a Agilent
Technologies 1200 Series instrument equipped with a Zorbax Eclipse Plus C18 (100 × 2.1
mm i.d. 1.8 μm) column and DAD detector (190 – 450 nm) in combination with a 6210
Time-of-Flight LC/MS instrument in positive ion mode. The samples were dissolved in pure
H2O (HPLC grade). The selected values were as follows: capillary voltage = 4 kV, gas
temperature = 350°C, drying gas = 12 L min−1, nebulizer pressure = 45 psig, and
fragmentator voltage = 70 V. Lobar LichroPrep Si 60 (40 – 63 μm) or LichroPrep RP-18
columns (Merck, Germany), coupled to a Waters RI 401 detector, were used for preparative
column chromatography. Microanalyses were performed using a Vario ELP III (Elementary,
Germany). Thin-layer chromatography was performed on pre-coated Merck silica gel 60
F254 and Merck RP-18 F254 plates. Reactions carried out employing microwave (MW)
conditions were performed using a Biotage Initiator Eight Robot with an automatic sampler
(USA and Sweden). Compounds were analyzed for purity (HPLC) using a Waters 1525
HPLC dual pump system equipped with an Alltech, Select™ degasser system, and dual λ
2487 UV-VIS detector. HPLC analyses were performed using two distinct methods:
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Method A: Octadecylsilica was used as the stationary phase (Symmetry C18 analytical
column, 4.6 mm – 150 mm, 5 μm, series no. 021336278136 37 (Waters Corporation,
Milford, Massachusetts 01757-3696, USA). Compounds were dissolved in 5% formic acid
in methanol. Final concentrations (concs.) were 0.1 – 0.5 mg/ml, and injection volumes were
10 μL. Eluent was prepared from the following solvents: 0.2% formic acid in water and
methanol. Gradient method runs from 10% to 90% MeOH over 15 min and back to 90%
aqueous over 5 min, followed by a 5 min 10% MeOH isocratic period were employed. The
analyses were performed at the UV max of the compounds (330 nm) to maximize
selectivity. For data processing, Empower software (Waters Corporation, Milford,
Massachusetts 01757-3696 U.S.A) was used. All compounds were > 95% pure.
Method B: Octadecylsilica was used as the stationary phase (Nucleosil C18 analytical
column, 4 mm – 150 mm, 5 μm, series no. 72923.40 (Macherey-Nagel GmbH & Co. KG,
Düren, Germany)). Compounds were dissolved in 5% formic acid in methanol. Final concs.
were 0.1–0.5 mg/ml, and the injection volume was 10μL. Eluent was prepared from 0.5%
formic acid in water and methanol. Gradient method runs from 10% to 90% MeOH over 15
min and back to 90% aqueous over 5 min, followed by a 5 min 10% MeOH isocratic period,
were performed. The analyses were performed at the UV max of the compounds (330 nm) to
maximize selectivity. For data processing, Empower software was used. All compounds
were > 95% pure.
5.1.1. 4,4′-Thiene-2,5-diyldibenzenecarboximidamide dihydrochloride (1)—Di-
nitrile 2 (vide infra) (2.24 g, 7.82 mmol) was suspended in freshly distilled THF (40 ml) and
treated with a solution of lithium bis(trimethylsilyl)amide (LHMDS, 5.24 g, 31.32 mmol) in
freshly distilled THF (40 ml). The reaction was stirred for 48 h at r.t., and the mixture was
clear and orange in color. The reaction mixture was cooled to 0°C, followed by the addition
of HCl-saturated ethanol (100 ml). The mixture was stirred overnight, diluted with ether,
and the resulting solid was collected by filtration (3.21 g). The crude product was purified
by neutralization with 1N NaOH, and collected by filtration. The di-amidine product (2.50 g,
7.81 mmol) was saturated with 36.7% HCl/EtOH (200 mL). The mixture was stirred for 12
h, diluted with ether, and the resulting solid was collected by filtration. Final product 1 was a
yellow amorphous powder. The yield was 2.99 g (97%, mp = 385 – 398°C) [21]. IR (KBr):
3254m, 3074m, 1668s, 1652m, 1605s, 1556w, 1533w, 1517w, 1485m, 1451w, 1415w,
1385w, 1286m, 844w, 832w, 800w, 771w, 747w, 704w cm−1. 1H NMR (200 MHz, d6-
DMSO): 9.473 (s, 2NH2 = C), 9.250 (s, 2NH2-C), 7.99-7.93 (m, 8H-Ar), 7.882 (s, H-C(3)
and H-C(4)). 13C NMR (50 MHz, CD3OD): 164.82, 142.48, 138.04, 129.16, 127.67, 126.80,
125.39. Anal. Calcd. for C18H18Cl2N4S × 0.3H2O: C, 54.14; H, 4.71; N, 14.03; S, 8.03.
Found: C, 54.23; H, 4.82; N, 13.35; S, 8.00.
5.1.2. 4,4′-Thiene-2,5-diyldibenzonitrile (2)—A reaction vessel containing a solution
of Pd(OAc)2 (20 mg, 0.09 mmol) and PPh3 (94.5 mg, 0.36 mmol) in DME (9 mL) was
stirred for10 min under Ar atmosphere. Following, 2,5-dibromothiophene (0.1 mL, 0.89
mmol) and 2M Na2CO3 (1.6 mL, 3.2 mmol) were added. After 5 min, 4-
cyanophenylboronic acid (290 mg, 1.97 mmol) was added, and the mixture was stirred for 2
h at 80°C in a MW reactor. The solvent was then removed under reduced pressure, and the
reaction mixture was suspended in dichloromethane (DCM), transferred to a separation
funnel, and washed well with saturated Na2CO3 solution (2 × 25 mL) containing 1 mL NH3.
The organic layer was collected, dried with anh. Na2SO4, and the solvent was filtered.
Subsequently, the solvent was removed under reduced pressure and intermediate 2 was
isolated using column chromatography (dry-flash, SiO2, eluent DCM), and collected as a
pale yellow amorphous powder. The yield was 240 mg (94%, mp = 282 – 284°C) [21]. IR
(KBr): 2925w, 2359w, 1535m, 1506m, 1380w, 1207s, 1150s, 1035s, 825s, 781m, 732m,
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702m cm−1. 1H NMR (200 MHz, CD3OD): 7.80-7.60 (m, 8H-Ar), 7.50-7.45 (s, H-C(3) and
H-C(4)). 13C NMR (50 MHz, CD3OD): 143.31, 137.90, 132.88, 126.36, 125.98, 118.64,
111.19. HPLC purity: method A, RT 15.397 min, area 99.03 %; method B: RT 14.656 min,
area 96.58 %.
5.1.3. 4,4′-Thiene-2,5-diyldibenzaldehyde (3)—Di-nitrile 2 (400 mg, 1.50 mmol) was
dissolved in dry toluene (50 mL) under Ar atmosphere, and DIBAH (9 mL, 1M in toluene)
was added drop-wise. After stirring at 0°C for 1 h, the reaction was quenched with 5%
H2SO4 (12 mL), and stirring was continued for 1 h at r.t. The reaction mixture was
transferred into a separation funnel as an EA emulsion. The organic layer was separated, and
the aqueous layer was extracted with DCM (8 × 50 mL). The combined organic layers were
washed with brine (2 × 10 mL) and dried over anh. Na2SO4. After filtration, the solvent was
removed under reduced pressure. Resulting intermediate 3, a pale yellow amorphous
powder, was sufficiently pure and was used in the next reaction step. The yield was 315 mg
(77%, mp = 148 – 152°C) [31]. IR (ATR): 3349w, 3198w, 3069m, 2923m, 2854m, 2764w,
1694s, 1599s, 1568m, 1498w, 1451w, 1423w, 1397w, 1346w, 1310w, 1280m, 1216m,
1167m, 1116w, 838m, 796m, 688w. 1H NMR (500 MHz, DMSO-d6): 10.01 (s, 2H-C=O),
7.96 (s, 8H-Ar), 7.90-7.80 (m, H-C(3) and H-C(4)). 13C NMR (125 MHz, DMSO-d6):
192.27, 142.98, 138.57, 135.24, 130.46, 127.65, 125.73. HRMS: m/z 293.06242
corresponding to molecular formula C18H12O2SH+ (error in ppm: −2.25).
5.1.4. 4,4′-[Thiene-2,5-diylbis(4,1-phenylenemethyleneammonioethane-2,1-
diylimino)]bis(7-chloroquinolinium) tetra(trifluoroacetate) (4a)—A mixture of N-
(7-chloroquinolin-4-yl)ethane-1,2-diamine (340 mg, 1.53 mmol), di-aldehyde 3 (150 mg,
0.51 mmol), and anh. AcOH (72 μL, 1.2 mmol) in MeOH/CH2Cl2 (2/1, v/v, 30 mL) was
stirred at r.t. for 14 h, followed by the addition of NaBH4 (240 mg, 6.34 mmol) in 40 mg
portions over 2 h. After stirring for an additional 6 h at r.t., the solvent was removed under
reduced pressure, and the product was isolated using column chromatography (dry-flash,
SiO2, gradient EtOAc/MeOH(NH3) 36/1 → 36/3). Fractions containing the product were
combined, and the crude product was dissolved in MeOH/CH2Cl2 (1/1, v/v. 15 mL),
followed by the addition of TFA (0.6 mL). The solvent and excess of TFA were removed
under reduced pressure, and the product was crystallized as a salt from MeOH, and dried at
40°C in a vacuum oven. Final product 4a was a yellow amorphous powder. The yield was
200 mg (34%, mp 242 – 244°C). IR (ATR): 3268w, 3030w, 2822w, 1678s, 1608s, 1569m,
1455m, 1426w, 1381w, 1246w, 1197s, 1132m, 838w, 802m, 721w cm−1. 1H NMR (200
MHz, DMSO-d6): 9.40 (bs, 2H-C(8′)), 8.67 (d, J = 6.8, 2H(2′)), 8.48 (d, J = 9.0, 2H(5′)),
8.02 (d, J = 2.2, H-C(3) and H-C(4)), 7.90-7.50 (m, 2H(6′), 8H-Ar), 6.99 (d, J = 6.8, 2H-
C(3′)), 4.30 (s, CH2-Ar), 3.94 (bs, 4H-C(9′), 3.35 (bs, 4H-C(10′). 13C NMR (50 MHz,
DMSO-d6): 159.26, 158.63, 158.01, 157.37, 155.07, 143.28, 141.75, 138.36, 137.60,
133.53, 130.86, 130.31, 126.45, 125.29, 124.90, 119.62, 118.99, 115.29, 113.67, 98.36,
49.21, 43.82. HRMS: m/z 703.2172 corresponding to molecular formula C40H36Cl2N6SH+
(error in ppm: −1.54). HPLC purity: method A, RT 6.912, area 98.95%; method B, RT
5.856, area 98.79%. Anal. Calcd. for C40H36Cl2N6S × 4TFA: C, 49.71%; H, 3.48%; N,
7.25%; S, 2.76%. Found: C, 49.56%; H, 3.63%; N, 7.03%; S, 2.52%.
5.1.5. 4,4′-[Thiene-2,5-diylbis(4,1-phenylenemethyleneammoniopropane-3,1-
diylimino)]bis(7-chloroquinolinium) tetra(trifluoroacetate) (4b)—Compound 4b
was synthesized according to the procedure used to generate 4a using di-aldehyde 3 (75 mg,
0.26 mmol) and N-(7-chloroquinolin-4-yl)propane-1,3-diamine (144 mg, 0.61 mmol), but
with a modification to the column chromatography solvent mixture. Specifically, crude
product was purified by column chromatography (dry-flash, SiO2 gradient EtOAc/
MeOH(NH3) (36/1 → 36/3)), and the product was crystallized from MeOH as a TFA salt.
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Final product 4b was a yellow amorphous powder. The yield was 150 mg (49%, mp = 165–
168°C). IR (ATR): 3612w, 3414w, 3273m, 3070m, 3076m, 2966m, 2816m, 2478w, 2366w,
2331w, 1674s, 1638w, 1613s, 1553m, 1456m, 1422w, 1368w, 1244w, 1199s, 1128s, 900w,
835m, 799m, 721m cm−1. 1H NMR (500 MHz, CD3OD): 8,38-8,35 (m, 2H-C(2′) and 2H-
C(8′)), 7,85-7,82 (m, 2H-C(5′)), 7,66 (d, J = 8,25, 2H-C(7) and 2H-C(11)), 7,61 (dd,
J=2,02, J=9,07, 2H-C(6′)), 7,50 (d, J=8,30, 2H-C(8) and 2H-C(10)), 7,38 (s, H-C(3) and H-
C(4)), 6,87 (d, J=7,20, 2H-C(3′)), 4,25 (s, 2CH2-Ar), 3,70 (t, J=6,85, 2H-C(9′)), 3,22 (t,
J=7,82, 2H-C(11′)), 2,24-2,18 (m, 2H-C(10′)). 13C NMR (125 MHz, CD3OD): 157.52,
143.94, 143.75, 141.01, 139.81, 136.38, 131.66, 131.25, 128.72, 126.87, 126.16, 125.82,
120.23, 119.16, 116.82, 99.65, 51.73, 45.42, 41.56, 25.54. HRMS: m/z 731.24576
corresponding to molecular formula C42H40Cl2N6SH+ (error in ppm: −3.74). HPLC purity:
method A, RT 7.191 min, area 97.64 %; method B: RT 6.113 min, area 99.08 %. Anal.
Calcd. for: C42H40Cl2N6S × 4TFA: C, 50.56%; H, 3.73%; N, 7.07%; S, 2.70%. Found: C,
50.40%; H, 3.85%; N, 6.92%; S, 2.57%.
5.1.6. 4,4′-[thiene-2,5-diylbis(4,1-phenylenemethyleneammoniobutane-4,1-
diylimino)]bis(7-chloroquinolinium) tetra(trifluoroacetate) (4c)—Compound 4c
was synthesized according to the procedure used to obtain 4b using di-aldehyde 3 (70 mg,
0.23 mmol) and N-(7-chloroquinolin-4-yl)butane-1,4-diamine (180 mg, 0.72 mmol), but
with an additional purification step. Specifically, the reaction mixture was initially sub-
purified using column chromatography (dry-flash, SiO2 gradient EtOAc/MeOH(NH3) 36/1
→ 36/3), and solvent was removed under reduced pressure. Following, the semi-crude
product was dissolved in MeOH/CH2Cl2 (1/1, v/v) with TFA added (0.5 mL). After
evaporation to dryness, the remaining solid was purified using a second column
chromatography procedure: LOBAR, RP-18 column, eluent MeOH/0.1% TFA. Final
product 4c was obtained as a yellow amorphous powder. The yield was 70 mg (24%, mp =
154 – 158°C). IR (ATR): 3388w, 3247m, 3034m, 2956m, 2824m, 2366w, 1680s, 1614s,
1561m, 1454m, 1424m, 1365w, 1202s, 1133s, 1016w, 901w, 834m, 800m, 767w, 718m cm
−1. 1H NMR (200 MHz, CD3OD): 8.40-8.35 (m, 2H-C(2′) and 2H-C(8′)), 7.86 (d, J = 1.5,
2H-C(5′)), 7.73 (d, J = 8.5, 2H-C(7) and 2H-C(11)), 7.66 (dd, J=2.0, J=9.0, 2×H-C(6′)),
7.53 (d, J = 8.5, 2H-C(8) and 2H-C(10)), 7.44 (s, H-C(3) and H-C(4)), 6.88 (d, J = 7.0, 2H-
C(3′)), 4.24 (s, 2CH2-Ar), 3.64 (bs, 2H-C(9′)), 3.15 (bs, 2H-C(12′)), 1.92-1.85 (m, 2H-
C(10′), 2H-C(11′)). 13C NMR (125 MHz, CD3OD): 162.65, 157.82, 144.33, 143.97,
141.17, 140.18, 136.72, 131.95, 128.85, 127.19, 126.50, 126.10, 120.48, 117.09, 99.91,
52.07, 48.17, 44.27, 26.28, 24.79. HRMS: m/z 759.27980 corresponding to molecular
formula C44H44Cl2N6SH+ (error in ppm: −1.21). Anal. Calcd. for C44H44Cl2N6S × 4 TFA ×
2H2O: C, 49.89%; H, 4.19%; N, 6.71%; S, 2.56%. Found: C, 49.74%; H, 4.25%; N, 6.50%;
S, 2.33%.
5.1.7. 4,4′-[thiene-2,5-diylbis(4,1-phenylenemethyleneammoniopentane-5,1-
diylimino)]bis(7-chloroquinolinium) tetra(trifluoroacetate) (4d)—Compound 4d
was synthesized according to the procedure used to obtain 4c using di-aldehyde 3 (70 mg,
0.23 mmol) and N-(7-chloroquinolin-4-yl)pentane-1,5-diamine (190 mg, 0.72 mmol). Note:
the additional purification step used to obtain 4c (vide supra) was also used. Final product
4d was obtained as a yellow amorphous powder. The yield was 70 mg (24%, mp = 146 –
149°C). IR (ATR): 3273w, 3033m, 2939m, 2825m, 2360w, 1670s, 1613s, 1454m, 1365w,
1198s, 1128s, 901w, 832w, 798m cm−1. 1H NMR (200 MHz, CD3OD): 8,42-8,28 (m, 2H-
C(2′) and 2H-C(8′)), 7,88-7,78 (m, 2H-C(5′)), 7.72 (d, J = 8.0, 2H-C(7) and 2H-C(11)),
7,64 (dd, J =1.8, J = 9.2, 2H-C(6′)), 7,53 (d, J = 8.0, 2H-C(8) and 2H-C(10)), 7,43 (s, H-
C(3) and H-C(4)), 6,83 (d, J = 6.8, 2H-C(3′)), 4,22 (s, 2CH2-Ar), 3,57 (t, J = 6.8, 4H-C(9′)),
3,15-3,00 (m, 4H-C(13′)), 1,90-1,70 (m, 4H-C(10′), 4H-C(12′)), 1,53-1,45 (m, 4H-
C(11′)). 13C NMR: 157.52, 144.12, 143.68, 140.91, 140.00, 136.45, 131.86, 128.62, 127.02,
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126.36, 125.98, 120.30, 116.84, 99.69, 51.84, 44.50, 28.44, 26.73, 24.86. HRMS: m/z
787.31125 corresponding to molecular formula C46H48Cl2N6SH+ (error in ppm: 0.20).
HPLC purity: method A: RT 8.071 min, area 97.10 %; method B: RT 6.918 min, area 97.59
%. Anal. Calcd. for: C46H48Cl2N6S × 4 TFA: C, 52.14%; H, 4.21%; N, 6.76%; S, 2.58%.
Found: C, 51.98%; H, 4.36%; N, 6.52%; S, 2.42%
5.2. Biology (HPLC-based assay to calculate BoNT/A LC inhibition)
A previously described HPLC in vitro assay was employed to determine inhibitor-mediated
BoNT/A LC inhibition kinetics [23–29], with slight modifications [23]. Briefly, the assay
utilized an N-terminal acetylated, C-terminal aminated, synthetic peptide identical in
sequence to residues 187–203 of SNAP-25. Compounds with intrinsic fluorescence
quenching capability do not interfere with the activity measurements of the assay because
substrate hydrolysis is determined by HPLC separation of the cleaved product and the intact
substrate, followed by measurement of the peak areas. All HPLC separations were
conducted on a Shimadzu Prominence Ultra Fast Liquid Chromatography XR system using
a Hypersil Gold Javelin c18 guard column (Thermo Fisher Scientific, Waltham, MA, USA)
and a Hypersil Gold c18 reverse-phase analytical column (50 × 2.1 mm, 1.9 μm) (Thermo
Fisher Scientific, Waltham, MA, USA). Peak areas were measured with LC solution
automated integration software (Shimadzu Corporation, Kyoto, Japan) and used to calculate
enzyme reaction rates. Assay mixtures consisted of 40 mM HEPES − 0.05% Tween (pH
7.3), recombinant BoNT/A LC (MetaBiologics, Madison, WI, USA), peptide substrate, 0.5
mg/ml Bovine Serum Albumin, 1 mM Dithiothreitol, 50 μM excess zinc, and 20 μM
inhibitor. The assays were run at 37°C, quenched via the addition of TFA, and analyzed by
reverse-phase HPLC.
For Ki value determination, plots of reaction velocity versus substrate conc., at multiple
inhibitor concs., were analyzed by global kinetic analysis. Data were fit to a competitive
inhibition model and analyzed by nonlinear regression analysis using the program GraphPad
Prism, version 5.01 (GraphPad Software, San Diego, CA, USA).
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• The discovery of a novel BoNT A inhibitor chemotype.
• The synthesis of submicromolar-range derivatives of a novel lead inhibitor.
• Replacing terminal amidines with secondary amines facilitates syntheses.
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Adding -(CH2)3-4,7-ACQ components translated lead BoNT/A LC inhibitor I into nM-
range derivatives, II was the most potent of the congeneric series [18].
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Reagents and conditions. i) 4-CN-PhB(OH)2, Pd(OAc)2, DME, Na2CO3(aq), MW, 80°C, 2h;
ii) DIBAH, PhMe, 1h, 0°C, Ar; iii) (step 1) NH2-(CH2)n-4,7-ACQ, NaBH4, AcOH, MeOH/
CH2Cl2 and (step 2) TFA; iv) (step 1) LHMDS, THF, r.t. and (step 2) HCl/EtOH.
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Table 1
BoNT/A LC inhibition constants for lead 1 and derivatives 4a – d.
Inhibitor Ki (μM)
1 10.88 ± 0.90 μM
4a 0.882 ± 0.11 μM
4b 0.302 ± 0.03 μM
4c 0.535 ± 0.60 μM
4d 0.889 ± 0.11 μM
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